Author: jezzabellemente

KUALA LUMPUR, Oct 1 — Biotalys NV, a transformative food and crop protection company has been awarded a €1.1 million research grant from Flanders Innovation & Entrepreneurship (VLAIO). (€1 = RM4.856)

According to a statement, the grant will run over three years and support the development of the Company’s novel protein-based bio-bactericides for the management of bacterial plant diseases.

“We are very pleased with the financial support and recognition from VLAIO and their commitment to continue to stimulate entrepreneurship and innovation in Belgium,” said Biotalys CSO, Hilde Revets.

“The funding will allow us to accelerate our research and development activities of our protein-based biocontrol solutions with completely new mechanisms-of-action for the management of bacterial plant diseases, including cankers, blight and spots,” added Revets.

“Bacterial diseases cause major damage to food and crops around the world and there is an urgent need for novel and safe solutions with consistent high efficacy to protect crops and reduce food waste,” said Biotalys CFO, Wim Ottevaere.

“We strongly believe that our bio-bactericide programme has the potential to address these needs and we look forward to progressing this innovative biocontrol further in development.”

More details at http://www.biotalys.com.

— BERNAMA

KUALA LUMPUR, Sept 25 — From elite athletes to medical patients, the therapeutic Kinesio Taping has been a boon.

While more than 40 years ago, Dr Kenzo Kase® invented the tape, there is now the Kinesio Tape for Canine designed to produce therapeutic benefits through the dog’s hair follicles, without the need for shaving.

According to a statement, the canine-specific attributes of this tape and taping patterns address a dog’s physiology. Kinesio Tape for Canine can be used on its own or with complimentary therapies to assist in rehabilitation or to address postural changes or musculoskeletal issues.

“Most of us at Kinesio are dog owners or dog lovers. As users and beneficiaries of taping on ourselves, we wondered how this might also benefit our canine friends and have been thrilled to discover and develop an entire methodology that can produce sometimes dramatically positive outcomes,”  said Kinesio Vice-President Elisa Kase.

Kinesio Tape for Canine uses 100 per cent cotton fabric and 100 per cent medical grade adhesive. Once applied, the tape can remain on the dogs 24 hours a day from two to five days.

Kinesio canine care is also integrated with a companion book and an innovative online workshop. The book and the Kinesio Canine Tape is now available globally through Kinesio’s network of International Distribution Partners in over 40 countries.

Kinesio Holding Corporation is a US-based manufacturer of unique therapeutic tapes sold globally.

— BERNAMA

CHONGQING, China, Sept. 24, 2020 /Xinhua-AsiaNet/–

Featuring touching natural beauty and radiating prosperity, the Rongchang District in west China’s Chongqing Municipality held a livestreaming promotion campaign as part of the 2020 Chongqing Showcase on Sept. 21. Livestreamed on over ten online platforms, the promotion featured rich local tourism and cultural products, gaining over 16.68 million views and 1,558,500 likes, according to the Publicity Department of Rongchang District.

The 2020 Chongqing Showcase is a large-scale cultural tourism promotion activity guided by the local government and widely participated by the society. Rongchang District of Chongqing is located at the junction of Sichuan and Chongqing. It was called Changzhou in ancient times and nicknamed a kingdom of cherry-apple trees. It was an important gathering place for a major immigration campaign in the Qing Dynasty and is known as “Living Fossil of Hakka Culture”. Rongchang, together with Foshan in Guangdong and Yixing in Jiangsu, is known as China’s three great pottery towns. Rongchang pottery is as famous as Jianshui pottery, Qinzhou pottery and Yixing pottery, which make up “China’s Four Best Potteries”. Rongchang folding fan, Suzhou silk fan and Hangzhou calligraphy and painting fan are also called “China’s Three Best Fans. The Xia cloth, one kind of hand woven linen, has been a traditional craft for thousands of years.

Rongchang is a city of emerging industries. It has a “6+1″industrial system dominated by consumer goods (food, medicine, ceramics, clothing), new materials, intelligent equipment, electronic information, digital block chain, sports health and high-tech agriculture and animal husbandry.

It is also a city of animal husbandry science and technology. There are first-class animal husbandry teaching and research institutions in China such as Rongchang Campus of Southwest University and Chongqing Academy of Animal Husbandry. 

Rongchang is an open and innovative city. Rongchang is a national pilot city to promote intellectual property development, a national foreign trade transformation and upgrading base (textile), and a demonstration area of innovation-driven development in Chongqing. Chengdu-Chongqing Railway, Chengdu-Chongqing Intercity Railway, Chengdu-Chongqing Expressway, Tongrong Expressway and Dane Expressway under construction run through the whole territory. Rongchang is currently actively integrating into the Belt and Road Initiative, the development of the western region, the Chengdu-Chongqing economic circle, and the new land and sea corridor in the western region. It is also pushing forward with the construction of inland open highland with Rongchang freight transport airport as the engine, and accelerating the construction of a multimodal transport system integrating railway, road, waterway and air.

Rongchang is a happy and livable city. There are Laixi River National Wetland Park, the “Top Ten Most Beautiful Towns in Chongqing” Wanling Ancient Town, the “Most Popular Tourist Destination” Antao Town, Xia Cloth Town, one of the first batch of intangible heritage towns in Chongqing, as well as the ancient Foshan Mountain with high and green mountains.

In recent years, Rongchang District has posted steady and healthy economic and social development. In the first half of this year, Rongchang District realized a GDP of 31.644 billion yuan, up 2.8 percent year on year, 2 percentage points higher than that of the whole city. At present, Rongchang is focusing on the goal of innovating and developing a new platform, a new high ground for industrial economy, a new pattern of opening and integration, and a new green and livable home. To speed up the construction of Chengdu-Chongqing integrated development demonstration zone, national integrated urban-rural development experimental zone, the country’s first national high-tech zone with agricultural and animal husbandry characteristics and the national animal husbandry science and technology city, and strive to become an important growth engine in the Chengdu-Chongqing economic circle.

http://mrem.bernama.com/viewsm.php?idm=38236

KUALA LUMPUR, Sept 23 — VistaJet recently announced the progress on its Sustainability in Aviation pledge, launched in January, to rapidly reduce its carbon footprint and explore all routes to higher levels of sustainability. 

According to a statement, VistaJet provides update on its eight pillars of sustainability including Fuel Consumption Reduction Technology and Fuel Efficient Booking System.

To date, using the FLIGHTKEYS 5D flight management system, the company has been able to optimise route, level and speed to reduce fuel consumption by eight per cent per flight.

Booking with at least one week’s notice helps to further improve fleet management, reducing unnecessary fuel burn. Customers who are more flexible on departure city airport selection have already helped to reduce movement around London airports by 20 per cent in 2019, cutting several tonnes of CO2.

In the same statement, the company also announced a market-leading partnership with SkyNRG, pioneer and global leader for sustainable aviation fuel. VistaJet is offering all of its global customers an access to sustainable aviation fuel, promoting substantial reductions in aviation carbon emissions, and increasing stable demand and availability worldwide.

Partnering with SkyNRG will offer VistaJet customers the most sustainable, cost-effective and scalable solution to decarbonise their flights, while helping to grow adoption across the entire industry.

VistaJet has dedicated itself to reducing its environmental footprint and affecting positive change through innovation. 

— BERNAMA

The two companies bring together cloud-based mobile technologies to improve the identification, screening and matching of patients to precision-based clinical oncology trials

RALEIGH, N.C. and COLUMBUS, Ohio, Sept 21 (Bernama-GLOBE NEWSWIRE) — PRA Health Sciences, Inc. (NASDAQ: PRAH) and Deep Lens, Inc., announced today a new strategic relationship to accelerate patient access and recruitment for oncology clinical trials. The relationship brings together best-in-class technologies that improve the identification, screening, and matching of cancer patients to precision-based clinical oncology trials on a global basis, with the combined solution being deployed to Microsoft Azure.

Deep Lens’ award-winning VIPER^TM patient screening platform is a breakthrough technology deployed by cancer centers, integrated delivery networks (IDNs), and community oncology networks to identify and match oncology patients to life saving clinical trials who would have otherwise fallen through the cracks and missed the opportunity to enroll. The differentiated technology and services model allows Deep Lens to deploy its software at cancer centers and site networks on a global basis, free of charge, to better give patients access to the therapies they need and deserve – while providing significant value by accelerating study timelines and bringing game-changing therapies to market sooner.

“More than 14,000 oncology trials are currently recruiting patients, but estimates are that only three to five percent of eligible patients actually participate,” said Kent Thoelke, Chief Scientific Officer at PRA Health Sciences. “The challenges facing clinical trial recruitment are multifaceted, and sponsors have been unable to determine where specific patients are in order to match them to studies — that is about to change. Using Deep Lens’ VIPER technology, the patient identification process will be streamlined by instantly analyzing data within electronic health records, pathology systems and genomic profiles to enable matching of cancer patients with suitable clinical trials.” 

The combined effort between PRA and Deep Lens brings a critical advancement to clinical trial matching to more efficiently connect eligible patients with potential clinical trials by leveraging artificial intelligence (AI) and machine learning via the VIPER platform.

How the VIPER Integration Works

VIPER enables cancer care teams, clinical trial sponsors and trial coordinators to immediately and automatically match patients based on the genetic profile of their cancers to the best precision therapies and oncology clinical trials.

VIPER is a HIPAA-compliant public cloud service that accesses data “behind the firewall” at participating sites and automatically ingests data from pathology systems at the time of diagnosis, and from electronic medical records and genetic test results from top genetic testing labs globally. VIPER acts as an AI-driven screening platform for research coordinators and care teams, while the de-identified data helps sponsors identify where in the process patients are being identified, where they may be disqualified and why they may or may not have enrolled in a trial once qualified. Currently, there is no workflow solution on the market that captures granular data about patients in their care continuum.

Once patients have been qualified for trials, the VIPER system will refer those patients to PRA’s industry leading Mobile Health Platform, also deployed on Azure, to provide an end-to-end patient-centric screening and trial management experience for providers globally.

The combination of VIPER’s artificial intelligence solution, workflow design, communication optimization and the research coordination services provides sponsors and research sites the best opportunity to connect the right patient, to the right trial, at the right time – it’s realization of personalized medicine.

“This will really move the needle in cancer research, and it will allow community oncology networks to compete with their much larger competitors at academic medical centers and comprehensive cancer centers,” Thoelke said. “With Microsoft Azure behind PRA and Deep Lens, we believe this relationship could create a game-changing model in cancer research, not only for patient screening but for the development of just-in-time networks and other new business models.”

“Deep Lens has grown dramatically with unique cloud technology and a business model that takes risk out of its deployment, and it has taken the vision of PRA to see the potential for a truly unique solution to come to market,” said Simon Arkell, Co-founder and President at Deep Lens. “With a global, industry-leading partner like PRA collaborating with Microsoft, we expect to exponentially grow our global footprint while dramatically increasing the success rates in oncology research. In turn, this will allow trial sponsors full visibility into the patient screening process so they can get their treatments to market much faster. Together, we will continue our mission to find the right patients for the right trials at the right time.”

About PRA Health Sciences

PRA Health Sciences is one of the world’s leading global contract research organizations by revenue, providing outsourced clinical development and data solution services to the biotechnology and pharmaceutical industries. PRA’s global clinical development platform includes more than 75 offices across North America, Europe, Asia, Latin America, South Africa, Australia and the Middle East and more than 17,500 employees worldwide. Since 2000, PRA has participated in approximately 4,000 clinical trials worldwide. In addition, PRA has participated in the pivotal or supportive trials that led to U.S. Food and Drug Administration or international regulatory approval of more than 95 drugs. To learn more about PRA, please visit www.prahs.com.

INVESTOR INQUIRIES: InvestorRelations@prahs.com

MEDIA INQUIRIES: Laurie Hurst, Sr. Director, Communications and Public Relations
hurstlaurie@prahs.com | +1 (919) 786-8435

About Deep Lens

Deep Lens is a software company focused on a groundbreaking approach to faster recruitment of the best-suited cancer patients to clinical trials. By identifying patients at the time of diagnosis and combining lab, EMR, and genomic data, VIPER, Deep Lens’ integrated cloud platform, provides care teams with visibility and workflows to accelerate recruitment and compress study timelines to bring game-changing therapies to market sooner. Growing with sponsors, providers, and strategic partners, Deep Lens challenges the status quo so that patients can get the therapies they want and deserve. For more information, visit www.deeplens.ai.

MEDIA INQUIRIES: Jessica Yingling, Ph.D., President, Little Dog Communications
jessica@litldog.com | +1.858.344.8091

SOURCE : PRA Health Sciences, Inc.